- FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)
- FDA Approves Newly Formulated OTC Primatene Mist (epinephrine) to Treat Mild Asthma
- FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma
- FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta
- FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer
- FDA Approves Dsuvia (sufentanil) Sublingual Tablets for Severe Pain
- FDA Approves Sympazan (clobazam) Oral Film for Adjunctive Treatment of Seizures Associated with Lennox-Gastaut Syndrome
- FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira
- FDA Approves Keytruda (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
- FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
- FDA Approves Bijuva (estradiol and progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
- FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza
- Spectrum Pharmaceuticals Receives FDA Approval of Khapzory (levoleucovorin) for Injection
- FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
- FDA Approves Talzenna (talazoparib) for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer